Outcomes after alemtuzemab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

E Morris; K Thomson; Charles Craddock; Premini Mahendra; Donald Milligan; G Cook; GM Smith; A Parker; S Schey; R Chopra; C Hatton; J Tighe; A Hunter; K Peggs; D Linch; A Goldstone; S Mackinnon

doi:10.1182/blood-2004-03-1105

Outcomes after alemtuzemab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

E Morris, K Thomson, Charles Craddock, Premini Mahendra, Donald Milligan, G Cook, GM Smith, A Parker, S Schey, R Chopra, C Hatton, J Tighe, A Hunter, K Peggs, D Linch, A Goldstone, S Mackinnon

Research output: Contribution to journal › Article

259 Citations (Scopus)

Original language	English
Pages (from-to)	3865-3871
Number of pages	7
Journal	Blood
Volume	104
DOIs	https://doi.org/10.1182/blood-2004-03-1105
Publication status	Published - 1 Jan 2004

Access to Document

10.1182/blood-2004-03-1105

Cite this

Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, GM., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A., & Mackinnon, S. (2004). Outcomes after alemtuzemab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, 3865-3871. https://doi.org/10.1182/blood-2004-03-1105

@article{56c1db23d48142b5a44228f5aeefa389,

title = "Outcomes after alemtuzemab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma",

author = "E Morris and K Thomson and Charles Craddock and Premini Mahendra and Donald Milligan and G Cook and GM Smith and A Parker and S Schey and R Chopra and C Hatton and J Tighe and A Hunter and K Peggs and D Linch and A Goldstone and S Mackinnon",

year = "2004",

month = jan,

day = "1",

doi = "10.1182/blood-2004-03-1105",

language = "English",

volume = "104",

pages = "3865--3871",

journal = "Blood",

issn = "1528-0020",

publisher = "American Society of Hematology",

}

Morris, E, Thomson, K, Craddock, C, Mahendra, P, Milligan, D, Cook, G, Smith, GM, Parker, A, Schey, S, Chopra, R, Hatton, C, Tighe, J, Hunter, A, Peggs, K, Linch, D, Goldstone, A & Mackinnon, S 2004, 'Outcomes after alemtuzemab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma', Blood, vol. 104, pp. 3865-3871. https://doi.org/10.1182/blood-2004-03-1105

TY - JOUR

T1 - Outcomes after alemtuzemab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

AU - Morris, E

AU - Thomson, K

AU - Craddock, Charles

AU - Mahendra, Premini

AU - Milligan, Donald

AU - Cook, G

AU - Smith, GM

AU - Parker, A

AU - Schey, S

AU - Chopra, R

AU - Hatton, C

AU - Tighe, J

AU - Hunter, A

AU - Peggs, K

AU - Linch, D

AU - Goldstone, A

AU - Mackinnon, S

PY - 2004/1/1

Y1 - 2004/1/1

UR - http://www.scopus.com/inward/record.url?scp=10244242523&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-03-1105

DO - 10.1182/blood-2004-03-1105

M3 - Article

C2 - 15304395

SN - 1528-0020

VL - 104

SP - 3865

EP - 3871

JO - Blood

JF - Blood

ER -